Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. | Italian ...

A first-time mom received backlash for saying she does not let her mom kiss her newborn. Doctors and pediatric infectious ...

The genetic modification therapy market presents key opportunities in developing specialized treatments for rare, inherited, ...

Adibelivir is a next generation helicase-primase inhibitor. The oral formulation is advancing toward Phase 2 development for genital herpes, while the parenteral formulation is dedicated exclusively ...